Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) shot up 5.9% during mid-day trading on Monday . The stock traded as high as $12.70 and last traded at $12.71. 106,969 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 402,392 shares. The stock had previously closed at $12.00.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price target on the stock. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $24.83.
View Our Latest Stock Report on KalVista Pharmaceuticals
KalVista Pharmaceuticals Price Performance
The company has a market cap of $646.11 million, a P/E ratio of -3.58 and a beta of 0.39. The business has a 50-day moving average of $11.55 and a two-hundred day moving average of $10.35.
Insider Transactions at KalVista Pharmaceuticals
In other news, CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the transaction, the chief executive officer now directly owns 278,855 shares of the company's stock, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were acquired at an average price of $9.22 per share, for a total transaction of $134,261.64. Following the completion of the purchase, the insider now owns 5,012,796 shares in the company, valued at $46,217,979.12. The trade was a 0.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company's stock.
Hedge Funds Weigh In On KalVista Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 3,767 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in KalVista Pharmaceuticals in the 4th quarter worth $44,000. Tower Research Capital LLC TRC lifted its position in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares during the period. Legal & General Group Plc grew its stake in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 1,494 shares during the last quarter. Finally, Martin Worley Group purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth about $86,000.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Further Reading
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
